A note before anything else. Retatrutide as discussed on this page is a research compound. It is not authorised as a medicine, it is not intended for human consumption, and nothing here is medical advice — speak to a doctor or pharmacist about anything concerning your own health. What follows is written for researchers and for readers trying to understand what has actually been published, not a guide to sourcing, dosing or using anything.
What is retatrutide, exactly?
Retatrutide is an investigational peptide designed to act on three separate hormone receptor pathways at once: GLP-1, GIP, and the glucagon receptor. That triple mechanism is what sets it apart in the research literature — most compounds in this space target one pathway or two, and retatrutide is one of the first widely studied molecules built around three simultaneously. It is developed by Eli Lilly and, as of this writing, remains in clinical trials rather than on any pharmacy shelf.
Supplied in research settings as a lyophilised powder for laboratory use, it is studied and sold on the research-peptide market as exactly that: a research chemical, not a finished product intended for use in or on the human body.
Why is "retatrutide dublin" one of the more searched versions of this query?
Because the interest in this molecule is unusually concentrated among people looking for city-specific, practical information rather than a general overview — how it compares to compounds they may already know, what the actual trial numbers say, and what the regulatory picture looks like from an Irish vantage point rather than a generic international one. A broad "what is retatrutide" article answers the first question and stops there. This file is built to answer the second and third as well, because that is what most of the traffic behind this specific search phrase is actually asking for.
What did the phase 2 trial actually find?
This is the part a generic overview usually skips, and it's worth being specific about because the numbers are public. The pivotal phase 2 trial, led by Jastreboff and colleagues, was published in the New England Journal of Medicine in 2023 and enrolled 338 adults with obesity over a 48-week treatment period. Across the dose arms studied, the trial reported substantial mean reductions in body weight relative to placebo by week 48, with the highest-dose group showing the largest effect size reported for any GLP-1-pathway compound in a phase 2 setting at that point. The trial is indexed on PubMed, and we'd rather point you to the primary source than restate a single number out of its context of dose arms, adverse-event profile and study design.
That result is also the reason retatrutide moved quickly into phase 3 trials, and it's the single most useful fact for a Dublin researcher trying to understand why this compound generates more search interest than most others in the same research category: the phase 2 data was unusually strong, which is precisely why the compound is not yet authorised for anything — larger, longer trials are still running to confirm it.
How does retatrutide differ from semaglutide and tirzepatide?
The distinction is the number of receptor pathways each molecule is built to act on, and it changes what question each one is actually answering in a research context.
Semaglutide — single pathway
Acts on the GLP-1 receptor alone. It's the most-studied compound in this category and the one already sold as a licensed prescription medicine, separate from any research-grade material. Our semaglutide file covers that licensed-versus-research distinction in full.
Tirzepatide — dual pathway
Adds the GIP receptor alongside GLP-1. Our tirzepatide file covers that dual-agonist research question and the batch checklist that applies to it.
Retatrutide — triple pathway
Adds a third target, the glucagon receptor, alongside GLP-1 and GIP. It's the newest of the three in clinical development and the one with the least mature dataset — phase 2 published, phase 3 ongoing, nothing authorised yet.
None of the three should be treated as interchangeable with either of the others in a research plan. More receptor pathways is not automatically "more" of the same effect — it's a distinct pharmacological question each time, and the maturity of the evidence differs sharply across the three.
Is retatrutide legal to buy or possess in Ireland?
Retatrutide holds no marketing authorisation anywhere in the world. It has not been reviewed or approved by the European Medicines Agency, and Ireland's own regulator, the HPRA, has not authorised it for any human use. That makes it a different category from semaglutide, which is a licensed prescription medicine dispensed through pharmacies under a doctor's supervision — retatrutide has no equivalent licensed product to compare against. It exists only as an investigational compound inside clinical trials, and as research-grade material sold for laboratory study.
The EMA's public medicines database, searchable at ema.europa.eu, is the place to check current authorisation status for any compound discussed on this register, including this one, rather than relying on a third-party summary. As of this writing, retatrutide does not appear there as an authorised medicine.
How do I verify a retatrutide batch's documentation?
The same standard applies here as to every other compound on this register: an independent Certificate of Analysis for the specific lot, not a generic document reused across every batch a supplier has sold.
Lot number matches the product
The number printed on the Certificate of Analysis should match what's printed on the vial you'd actually receive, not sit disconnected from it.
Purity is reported by HPLC, method named
A percentage on its own proves little. The document should name the method — high-performance liquid chromatography — alongside the figure it produced.
Identity is confirmed by LC-MS
A separate test, liquid chromatography–mass spectrometry, confirming the molecule matches retatrutide's expected mass. Purity and identity are two different questions, and both need answering.
The testing laboratory is named and independent
Look it up. A results sheet produced in-house by the seller is a specification, not third-party verification, however professional it looks.
A supplier confident in a genuine batch hands over this documentation without friction and before payment is discussed. One that can't, or won't, has told you most of what you need to know.
Where does retatrutide stand in the approval pipeline?
Following the phase 2 results, retatrutide moved into a phase 3 programme studying larger populations over longer periods, the standard next step before any regulator — the EMA in Europe, the HPRA in Ireland — would consider a marketing authorisation application. That process takes years, not months, and a positive phase 2 result is not a guarantee of eventual approval; several compounds with promising early data have not made it through phase 3 or the subsequent regulatory review. Until an authorisation is actually granted and published on the EMA's register, retatrutide remains, in every jurisdiction including Ireland, an unauthorised investigational compound.
Frequently asked questions
Is retatrutide legal to buy or possess in Ireland?
No medicine containing retatrutide is authorised in Ireland or anywhere else. It is not sold in pharmacies and is not intended for human use — it exists only inside clinical trials and as a research-grade compound for laboratory study.
How is retatrutide different from tirzepatide and semaglutide?
It's the number of receptor pathways each is built to act on: one for semaglutide, two for tirzepatide, three for retatrutide. Three separate research questions with three different levels of evidence maturity, not three strengths of the same thing.
Where can I read the original retatrutide trial data?
The phase 2 results were published in the New England Journal of Medicine in 2023 and are indexed on PubMed, linked above. We'd recommend reading the primary source directly rather than a secondhand summary, this one included.
We keep the single source we've reviewed against our documentation standard behind one clearly marked page, separate from every guide on this register.
See the verified source